Replies to post #195444 on Cytodyn Inc (CYDY)

[Black-Ops]

All or almost all the CYDY info is claimed to be factual. Well now, any young broker ever said something like this on a phone call; that broker would be fired in two seconds for his spurious behavior. That CYDY opinion and 2$ will buy a cheap popcorn. Yes, the CYDY prediction has no value. Its drive by rear view mirror investment drive by assault job. I have given extensive free tutorials about this investor crutch. It is worthless.

Stock prices are ruled by the future. CYDY will rule. My opinion.

My opinion is my opinion. I will add, I have a very sharp memory. What were we talking about? Oh yes, I wanted another coffee.

[JPG77]

WHAT??? LMAO!!!

NASH is not showing good data

CytoDyn announces POSITIVE results from open label NASH trial of leronlimab

Vancouver, Washington
Friday, November 26, 2021

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reported data from its trial treating NASH (nonalcoholic steatohepatitis) open label with leronlimab.

Leronlimab open label NASH results continue to show reductions in fat and fibrosis suggestive of a potential therapy not only for NAFLD (Non-Alcoholic Fatty Liver Deposit) but also in NASH. Fat reductions by proton density fat fraction PDFF up to 45% along with reductions in fibrosis up to 8% by CT1 were noted from baseline after just 14 weeks of treatment. The reductions in fibrosis were seen in both severe and mild-moderate NASH cases.

Nader Pourhassan, Ph.D., CytoDyn’s president and chief executive officer, stated, “Though numerous drugs have been evaluated in clinical trials, there have been no approvals by the US Food and Drug Administration for treating biopsy-proven NASH. We are encouraged by the continued results and look forward to presenting the full trial results after database lock. We believe this reported data is an exciting step forward in research and demonstrates the potential of leronlimab for inhibiting the liver fibrosis associated with NASH. CytoDyn will now file for Fast Track Designation for both the indications of NASH and NAFLD. Once the full results are reported, which we anticipate to be available in mid-December, we may proceed to file a phase 3 protocol with the FDA and request accelerated approval.”

[The Dark KnaDDir]

Yes and CYDY will writing off expiring leronlimab from inventory as it is already doing now.